Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system

Pappanaicken Kumaresan, Mathew Figliola, Judy S. Moyes, M. Helen Huls, Priti Tewari, Elizabeth J. Shpall, Richard Champlin, Laurence J N Cooper

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection occurring after allogeneic hematopoietic stem-cell transplantation. Viral-specific T cells from allogeneic donors, including third party donors, can be propagated ex vivo in compliance with current good manufacturing practice (cGMP), employing repeated rounds of antigendriven stimulation to selectively propagate desired T cells. The identification and isolation of antigen-specific T cells can also be undertaken based upon the cytokine capture system of T cells that have been activated to secrete gamma-interferon (IFN-γ). However, widespread human application of the cytokine capture system (CCS) to help restore immunity has been limited as the production process is time-consuming and requires a skilled operator. The development of a second-generation cell enrichment device such as CliniMACS Prodigy now enables investigators to generate viral-specific T cells using an automated, less labor-intensive system. This device separates magnetically labeled cells from unlabeled cells using magnetic activated cell sorting technology to generate clinical-grade products, is engineered as a closed system and can be accessed and operated on the benchtop. We demonstrate the operation of this new automated cell enrichment device to manufacture CMV pp65-specific T cells obtained from a steady-state apheresis product obtained from a CMV seropositive donor. These isolated T cells can then be directly infused into a patient under institutional and federal regulatory supervision. All the bio-processing steps including removal of red blood cells, stimulation of T cells, separation of antigen-specific T cells, purification, and washing are fully automated. Devices such as this raise the possibility that T cells for human application can be manufactured outside of dedicated good manufacturing practice (GMP) facilities and instead be produced in blood banking facilities where staff can supervise automated protocols to produce multiple products.

Original languageEnglish (US)
Article numbere52808
JournalJournal of Visualized Experiments
Volume2015
Issue number104
DOIs
StatePublished - Oct 5 2015
Externally publishedYes

Fingerprint

T-cells
Cytomegalovirus
Cytokines
T-Lymphocytes
Equipment and Supplies
Tissue Donors
Antigens
Blood
Cells
Interferons
Blood Banks
Blood Component Removal
Adoptive Transfer
Cell Separation
Hematopoietic Stem Cell Transplantation
Opportunistic Infections
Cytomegalovirus Infections
Pathogens
Stem cells
Sorting

Keywords

  • Anti-viral immunotherapy
  • Automated cell enrichment device
  • Bioprocessing
  • CMV-specific T cells
  • Cytokine-capture system (CCS)
  • IFN-gamma secreting T cells
  • Immunology
  • Issue 104
  • Magnetic-activated cell sorting technology
  • Pp65

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemical Engineering(all)
  • Immunology and Microbiology(all)
  • Neuroscience(all)

Cite this

Kumaresan, P., Figliola, M., Moyes, J. S., Huls, M. H., Tewari, P., Shpall, E. J., ... Cooper, L. J. N. (2015). Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. Journal of Visualized Experiments, 2015(104), [e52808]. https://doi.org/10.3791/52808

Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. / Kumaresan, Pappanaicken; Figliola, Mathew; Moyes, Judy S.; Huls, M. Helen; Tewari, Priti; Shpall, Elizabeth J.; Champlin, Richard; Cooper, Laurence J N.

In: Journal of Visualized Experiments, Vol. 2015, No. 104, e52808, 05.10.2015.

Research output: Contribution to journalArticle

Kumaresan, P, Figliola, M, Moyes, JS, Huls, MH, Tewari, P, Shpall, EJ, Champlin, R & Cooper, LJN 2015, 'Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system', Journal of Visualized Experiments, vol. 2015, no. 104, e52808. https://doi.org/10.3791/52808
Kumaresan, Pappanaicken ; Figliola, Mathew ; Moyes, Judy S. ; Huls, M. Helen ; Tewari, Priti ; Shpall, Elizabeth J. ; Champlin, Richard ; Cooper, Laurence J N. / Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. In: Journal of Visualized Experiments. 2015 ; Vol. 2015, No. 104.
@article{0daf949de5af43bb882c833eba03790f,
title = "Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system",
abstract = "The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection occurring after allogeneic hematopoietic stem-cell transplantation. Viral-specific T cells from allogeneic donors, including third party donors, can be propagated ex vivo in compliance with current good manufacturing practice (cGMP), employing repeated rounds of antigendriven stimulation to selectively propagate desired T cells. The identification and isolation of antigen-specific T cells can also be undertaken based upon the cytokine capture system of T cells that have been activated to secrete gamma-interferon (IFN-γ). However, widespread human application of the cytokine capture system (CCS) to help restore immunity has been limited as the production process is time-consuming and requires a skilled operator. The development of a second-generation cell enrichment device such as CliniMACS Prodigy now enables investigators to generate viral-specific T cells using an automated, less labor-intensive system. This device separates magnetically labeled cells from unlabeled cells using magnetic activated cell sorting technology to generate clinical-grade products, is engineered as a closed system and can be accessed and operated on the benchtop. We demonstrate the operation of this new automated cell enrichment device to manufacture CMV pp65-specific T cells obtained from a steady-state apheresis product obtained from a CMV seropositive donor. These isolated T cells can then be directly infused into a patient under institutional and federal regulatory supervision. All the bio-processing steps including removal of red blood cells, stimulation of T cells, separation of antigen-specific T cells, purification, and washing are fully automated. Devices such as this raise the possibility that T cells for human application can be manufactured outside of dedicated good manufacturing practice (GMP) facilities and instead be produced in blood banking facilities where staff can supervise automated protocols to produce multiple products.",
keywords = "Anti-viral immunotherapy, Automated cell enrichment device, Bioprocessing, CMV-specific T cells, Cytokine-capture system (CCS), IFN-gamma secreting T cells, Immunology, Issue 104, Magnetic-activated cell sorting technology, Pp65",
author = "Pappanaicken Kumaresan and Mathew Figliola and Moyes, {Judy S.} and Huls, {M. Helen} and Priti Tewari and Shpall, {Elizabeth J.} and Richard Champlin and Cooper, {Laurence J N}",
year = "2015",
month = "10",
day = "5",
doi = "10.3791/52808",
language = "English (US)",
volume = "2015",
journal = "Journal of Visualized Experiments",
issn = "1940-087X",
publisher = "MYJoVE Corporation",
number = "104",

}

TY - JOUR

T1 - Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system

AU - Kumaresan, Pappanaicken

AU - Figliola, Mathew

AU - Moyes, Judy S.

AU - Huls, M. Helen

AU - Tewari, Priti

AU - Shpall, Elizabeth J.

AU - Champlin, Richard

AU - Cooper, Laurence J N

PY - 2015/10/5

Y1 - 2015/10/5

N2 - The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection occurring after allogeneic hematopoietic stem-cell transplantation. Viral-specific T cells from allogeneic donors, including third party donors, can be propagated ex vivo in compliance with current good manufacturing practice (cGMP), employing repeated rounds of antigendriven stimulation to selectively propagate desired T cells. The identification and isolation of antigen-specific T cells can also be undertaken based upon the cytokine capture system of T cells that have been activated to secrete gamma-interferon (IFN-γ). However, widespread human application of the cytokine capture system (CCS) to help restore immunity has been limited as the production process is time-consuming and requires a skilled operator. The development of a second-generation cell enrichment device such as CliniMACS Prodigy now enables investigators to generate viral-specific T cells using an automated, less labor-intensive system. This device separates magnetically labeled cells from unlabeled cells using magnetic activated cell sorting technology to generate clinical-grade products, is engineered as a closed system and can be accessed and operated on the benchtop. We demonstrate the operation of this new automated cell enrichment device to manufacture CMV pp65-specific T cells obtained from a steady-state apheresis product obtained from a CMV seropositive donor. These isolated T cells can then be directly infused into a patient under institutional and federal regulatory supervision. All the bio-processing steps including removal of red blood cells, stimulation of T cells, separation of antigen-specific T cells, purification, and washing are fully automated. Devices such as this raise the possibility that T cells for human application can be manufactured outside of dedicated good manufacturing practice (GMP) facilities and instead be produced in blood banking facilities where staff can supervise automated protocols to produce multiple products.

AB - The adoptive transfer of pathogen-specific T cells can be used to prevent and treat opportunistic infections such as cytomegalovirus (CMV) infection occurring after allogeneic hematopoietic stem-cell transplantation. Viral-specific T cells from allogeneic donors, including third party donors, can be propagated ex vivo in compliance with current good manufacturing practice (cGMP), employing repeated rounds of antigendriven stimulation to selectively propagate desired T cells. The identification and isolation of antigen-specific T cells can also be undertaken based upon the cytokine capture system of T cells that have been activated to secrete gamma-interferon (IFN-γ). However, widespread human application of the cytokine capture system (CCS) to help restore immunity has been limited as the production process is time-consuming and requires a skilled operator. The development of a second-generation cell enrichment device such as CliniMACS Prodigy now enables investigators to generate viral-specific T cells using an automated, less labor-intensive system. This device separates magnetically labeled cells from unlabeled cells using magnetic activated cell sorting technology to generate clinical-grade products, is engineered as a closed system and can be accessed and operated on the benchtop. We demonstrate the operation of this new automated cell enrichment device to manufacture CMV pp65-specific T cells obtained from a steady-state apheresis product obtained from a CMV seropositive donor. These isolated T cells can then be directly infused into a patient under institutional and federal regulatory supervision. All the bio-processing steps including removal of red blood cells, stimulation of T cells, separation of antigen-specific T cells, purification, and washing are fully automated. Devices such as this raise the possibility that T cells for human application can be manufactured outside of dedicated good manufacturing practice (GMP) facilities and instead be produced in blood banking facilities where staff can supervise automated protocols to produce multiple products.

KW - Anti-viral immunotherapy

KW - Automated cell enrichment device

KW - Bioprocessing

KW - CMV-specific T cells

KW - Cytokine-capture system (CCS)

KW - IFN-gamma secreting T cells

KW - Immunology

KW - Issue 104

KW - Magnetic-activated cell sorting technology

KW - Pp65

UR - http://www.scopus.com/inward/record.url?scp=84946422759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946422759&partnerID=8YFLogxK

U2 - 10.3791/52808

DO - 10.3791/52808

M3 - Article

AN - SCOPUS:84946422759

VL - 2015

JO - Journal of Visualized Experiments

JF - Journal of Visualized Experiments

SN - 1940-087X

IS - 104

M1 - e52808

ER -